Search

Displaying results 4271 - 4280 of 4359 in total
  1. Drug

    Mepiprazole

    go.drugbank.com/drugs/DB09197
    Experimental

    It acts as a 5-HT2A and α1-adrenergic receptor antagonist, and has also been shown to inhibit the reuptake and induce the release of serotonin, dopamine, and norepinephrine to varying extents.

  2. Drug

    Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

    go.drugbank.com/drugs/DB15729
    Investigational

    Lipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro.

  3. Drug

    Surotomycin

    go.drugbank.com/drugs/DB12076
    Investigational

    It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections.

  4. Drug

    Lanoteplase

    go.drugbank.com/drugs/DB06245
    Experimental

  5. Drug

    Chlorotoxin I-131

    go.drugbank.com/drugs/DB05462
    Investigational

    The synthetic version of this peptide has been manufactured and covalently linked to iodine 131 as a means of targeting radiation to tumor cells in the treatment of brain cancer.

  6. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    As of August, 2020 the candidate is in Phase II clinical trials[A219758].

  7. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment

  8. Drug

    PR-104

    go.drugbank.com/drugs/DB05968
    Investigational

  9. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  10. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha). It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic ...